Unii-4bmh7izt98

한글명:Unii-4bmh7izt98

카스 번호856676-23-8

상품명:Unii-4bmh7izt98

CBNumberCB62494614

분자식C22H28ClNO5

포뮬러 무게421.91442

MOL 파일856676-23-8.mol

화학적 성질

녹는점	210-212°C
저장 조건	Hygroscopic, -20°C Freezer, Under Inert Atmosphere
용해도	메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태	고체
물리적 상태	단단한 모양
색상	흰색에서 황백색까지
안정성	흡습성

위험 및 안전 성명

HS 번호

2923100000

그림문자(GHS)

Unii-4bmh7izt98 화학적 특성, 용도, 생산

개요
Choline fenofibrate, a salt formulation of fenofibric acid, is a lipid regulating agent available as delayed release capsules for oral administration. It is indicated in combination with a statin to reduce TG and increase high-density lipoprotein cholesterol (HDL-C) in patients with mixed dyslipidemia and coronary heart disease (CHD) or a CHD-risk equivalent who are optimal for statin therapy to achieve their lowdensity lipoprotein cholesterol (LDL-C) goal. In addition, choline fenofibrate is indicated as monotherapy in patients with severe hypertriglyceridemia to reduce TG, and in patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated LDL-C, total cholesterol, TG, apolipoprotein B, and to increase HDL-C. Fenofibric acid is also the active metabolite of fenofibrate (Tricor), which has been previously marketed for the treatment of hypercholesterolemia and hypertriglyceridemia. The primary mode of action of fenofibric acid is through the activation of the nuclear transcription factor PPARa, predominantly expressed in tissues that metabolize fatty acids, such as the liver, kidney, heart, and muscle.
On activation by binding of the fibrate, PPARa binds as heterodimers with retinoid X receptor (RXR), which subsequently recognizes and binds to specific PPARa-response elements leading to modulation of expression of the target genes. In particular, the activity of lipoprotein lipase is increased and synthesis of apoprotein C-III is decreased, which together enhance the clearance of circulating TG-rich lipoproteins. The resulting fall in TG produces an alteration in the size and composition of LDL from small dense particles to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Choline fenofibriate acid is contraindicated in patients with severe renal impairment.
화학적 성질
White Solid
부작용
The most common adverse reactions observed with the use of fenofibric acid alone or in combination with a statin are headache, back pain, nasopharyngitis, nausea, myalgia, diarrhea, and upper respiratory tract infection.

Unii-4bmh7izt98 공급 업체

Unii-4bmh7izt98 관련 검색

Send Inquriy